123 results about "Attenuated vaccine" patented technology

The invention discloses a toxoplasma gondii attenuated vaccine strain RH delta rop67 as well as a construction method and application thereof, and belongs to the technical field of parasitic disease prevention and control and biological product preparation. The attenuated vaccine strain is constructed by performing targeted knockout on the ROP67 gene in a toxoplasma gondii strain RH delta ku80 through a CRISPR / Cas9 mediated gene editing technology. Compared with a wild type strain, the attenuated vaccine strain shows remarkable attenuation characteristic and good immunogenicity. A test result shows that the attenuated vaccine strain can induce a host to generate specific immune response mainly based on cellular immunity, maintains a protection effect on toxoplasma gondii infection in a relatively long immune period, and has a protection effect on tachyzoite infection and a chronic infection stage of toxoplasma gondii strains with different virulence; the survival ability of a host to tachyzoite infection can be improved, and the formation level of cysts in tissues is reduced. The invention provides a technical scheme with long-term immune potential for research and development of toxoplasma gondii attenuated vaccines.

The invention discloses a freeze-drying protection system for an influenza live attenuated vaccine. The freeze-drying protection system is composed of a buffer solution and auxiliary materials. The freeze-dried powder is safe and effective, has a relatively good protection effect on an influenza attenuated strain, is relatively low in virus loss before and after freeze-drying, and has good storage stability.

The invention discloses construction and application of a streptococcus suis serotype 2 cps2C gene knockout mutant strain. The invention relates to a streptococcus suis serotype 2 cps2C gene knockout mutant strain 05ZYH33 delta cps2C. A coding gene, from the 31st site to the 1000th site, of the cps2C gene in the strain 05ZYH33 is replaced by a spectinomycin resistance gene cassette SpcR. The mutant strain 05ZYH33 delta cps2C is applied to preparation of a streptococcus suis type 2 attenuated vaccine and a subunit vaccine. The capsule of the mutant strain 05ZYH33 delta cps2C is obviously reduced; in-vitro experiments show that the macrophage phagocytosis resistance of the mutant strain 05ZYH33 delta cps2C is reduced, and animal toxicity test results show that the toxicity of the mutant strain is obviously reduced. The mutant strain provides an important clue for screening of protective antigens of multivalent subunit vaccines, and can be applied to development of S.suis attenuated vaccines and multivalent subunit vaccines.

This document provides details regarding the construction of a recombinant African swine fever virus (ASFV) live attenuated vaccine for the prevention of African swine fever (ASF) caused by various viral strains of ASFV such as the highly virulent Georgia 2007 isolate (“ASFV-G”). Exemplary vaccines comprise an ASFV-GΔI177l modified virus, i.e., a recombinant ASFV-G modified by deletion of a portion of the I177L ORF such that the I177L gene is rendered non-functional.

The invention discloses a cryptosporidium parvum AOX gene deleted strain as well as a construction method and application thereof, and the cryptosporidium parvum AOX gene deleted strain disclosed by the invention is obtained by editing an AOX gene of cryptosporidium parvum through a gene editing technology. According to the gene editing technology, the cryptosporidium parvum AOX gene is knocked out by using a CRISPR / Cas9 gene editing technology, so that a cryptosporidium parvum AOX gene deleted strain is obtained; the AOX gene is found to be related to insect toxicity for the first time, and the infection intensity of an AOX gene deleted insect strain in a gamma interferon gene knockout mouse body is remarkably reduced. Research shows that after the AOX gene is deleted from the wild type cryptosporidium parvum IIdA20G1 subtype strain, the strain has the advantage that the toxicity is obviously weakened, and can be used for preparing cryptosporidium parvum attenuated vaccines so as to prevent cryptosporidium parvum infection.

There are SARS coronavirus 2 recombinant vectors derived from a GH clade SARS coronavirus 2 Korean isolate, which express distinct reporter genes, and the production method thereof. A full-length clone of a SARS coronavirus 2 Korean isolate or a derivative thereof, according to one embodiment, can be used as a standard material for evaluating the efficacy of therapeutic agents and vaccines in cell lines and animal models while maintaining infectivity and replication capacity when restored to viruses, can be used to develop a large-scale testing method for therapeutic agent development, and can be used to develop attenuated vaccine strains. In addition, a SARS coronavirus 2 recombinant vector derived from a Korean isolate or a derivative thereof, expressing a reporter gene, can be used for high-capacity, rapid drug screening in the development of antibody therapeutic agents and antiviral agents.

The application discloses a PEDV chimeric virus attenuation identification method based on reverse genetic operation and application of screening potential attenuated vaccine, and the PEDV chimeric virus CHM2013-SP BJ , CHM2013- BJ , CHM2013-SP BJ -ORF3 CHM , CHM2013-SP BJ -E CHM , CHM2013-SP BJ -M CHM , CHM2013-SP BJ -N CHM and CHM2013-(S+ORF3) BJ are constructed and rescued, loss-of-function test and gain-of-function test are carried out, and the attenuated chimeric virus CHM2013-SP BJ -ORF3 CHM and CHM2013-SP BJ -M CHM are obtained, and it is disclosed that the S gene of the PEDV variant BJ2011C promotes virus pathogenicity in cooperation with the ORF3, E and M genes, and the ORF3 gene is the most critical.

This invention discloses a candidate strain of *R. anatipestifer* double-gene deletion attenuated vaccine, its construction method, and its application. The candidate strain of *R. anatipestifer* double-gene deletion attenuated vaccine is *R. anatipestifer* strain CH-1. B739_RS01935-B739_RS07625 A candidate attenuated live vaccine strain with double gene deletion, deposited at the China Center for Type Culture Collection (CCTCC) on May 22, 2025, with accession number CCTCC NO: M20251080, at Wuhan University, Wuhan, China, has been deposited on that date. The attenuated live strain constructed in this invention showed no significant impact on the weight gain of ducklings after immunization, demonstrating good safety. Furthermore, the protection rate against challenge with the wild-type virulent RACH-1 strain reached 83.3% after immunization, indicating excellent immunoprotective efficacy.

The invention provides an application of trichostatin A in promotion of RNA virus proliferation, and belongs to the field of chemical medicines. The invention discloses a novel application of trichostatin A. The trichostatin A can effectively promote the-1 Ribosomal Frameshift process of RNA viruses, can effectively promote replication and proliferation of the RNA viruses, can be used for preparing products for promoting proliferation of the RNA viruses and can be used for producing and preparing RNA virus inactivated vaccines or attenuated vaccines, and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses and the application of the trichostatin A in promoting proliferation of the RNA viruses. And the production cost can be effectively reduced, the production period is shortened, and wide application prospects and economic values are achieved.

The use of anti-HPV immunogens and nucleic acid molecules encoding them for the treatment and prevention of RRP is disclosed.SOLUTION: Pharmaceutical compositions, recombinant vaccines comprising the DNA plasmids, and live attenuated vaccines are disclosed, as well as methods of inducing an immune response to treat or prevent RRP.SELECTED DRAWING: Figure 1

The application discloses a Toxoplasma gondii DAHPS gene deletion vaccine strain and application thereof. The application provides a Toxoplasma gondii gene knockout strain, which is obtained by directly knocking out a 3-deoxy-D-arabino-heptulosonate-7-phosphate synthase TgDAHPS gene of the Toxoplasma gondii through a gene editing technology, the gene ID of the TgDAHPS gene is TGGT1_221260, and the nucleotide sequence is shown as SEQ ID NO. 1. The gene deletion strain Δdahps provided by the application can grow normally in vitro, does not reproduce in a host in vivo, and is almost non-toxic. After immunization of the Δdahps strain, the host can be induced to have good immune protection. The Δdahps has the advantages of weak virulence and almost no reproduction in vivo as the attenuated vaccine strain of the Toxoplasma gondii, can improve the resistance of the host to wild Toxoplasma gondii, and can be used for preventing the infection of the Toxoplasma gondii in humans and animals, and has important significance for developing more Toxoplasma gondii vaccines.

The invention discloses a porcine epidemic diarrhea and porcine rotavirus (G9 type) bigeminy attenuated vaccine and a preparation method thereof, and relates to the technical field of veterinary biological products. According to the present invention, dominant genotype strains such as PEDV G2 type KQ01 strain (the preservation number is CCTCC NO: V202005) and PoRV G9 type CH09 strain (the preservation number is CCTCC NO: V202191) are adopted as parent strains, a cell continuous passage method is adopted to carry out passage attenuation, and the virus content, the purity, the specificity, the hereditary stability, the safety and the immunogenicity are systematically inspected during the passage process; and then, carrying out proliferation process research on passage attenuated strains PEDV HB17-R and PoRV JS01-R in a bioreactor, harvesting a cell culture, mixing the two antigens according to a proper ratio, adding a proper amount of a stabilizer, and carrying out a freeze vacuum drying process to obtain the high-purity PoRV-HB17-R / PoRV-HB17-R / PoRV-HB17-R / PoRV-HB17-R / PoRV-JS01-R composite antigen. The bigeminy attenuated vaccine is highly matched with current dominant prevalent strains (PEDV G2 type and PoRV G9 type), is based on a suspension culture technology and has both safety and high efficiency.

The invention discloses a toxoplasma gondii double-gene deletion attenuated vaccine strain as well as a construction method and application thereof. The toxoplasma gondii double-gene deletion attenuated vaccine strain is constructed by deleting a ku80 gene and a CDC14 gene on the basis of a toxoplasma gondii type II PLK strain, and is named as PLK [delta] TgKu80 [delta] TgCDC14 ([delta] CDC14 for short), and experimental results show that the pathogenicity of the strain is remarkably reduced after the CDC14 gene is knocked out. In order to further explore the immune protection effect on toxoplasma gondii acute infection mice, secondary acute infection is carried out on mice immunized with delta CDC14 strains, and the result shows that compared with non-immunized group mice, no immunized mice die within 30 days, and all non-immunized mice die within 13 days. Therefore, the double-gene deletion attenuated vaccine strain has the potential of being used as a vaccine, and an effective technical means is provided for preventing toxoplasma gondii infection.

This invention provides a live attenuated Brucella vaccine strain M5Δ pyrE Its construction methods and applications belong to the field of biotechnology. The M5... pyrE The strain was obtained by knocking out Brucella mesenteriae strain M5. pyrE Genetically constructed and deposited at the China Center for Type Culture Collection. This invention discovers that... pyrE The gene is associated with Brucella virulence; knocking out this gene significantly weakens Brucella virulence and reduces its intracellular and mouse viability. Compared to the existing vaccine strain M5-9026, M5... pyrE The strain exhibits superior immunoprotective effects, effectively inducing humoral and Th1 cellular immune responses, and demonstrates good safety. The M5 strain constructed in this invention... pyrE This strain has promising potential as a candidate strain for a live attenuated vaccine to prevent brucellosis in animals.

This invention relates to the field of biotechnology, and more particularly to a mutant of the Rift Valley fever virus L protein and its applications. The amino acid sequence of the mutant is based on the amino acid sequence shown in SEQ ID NO:1, with mutations made at position 1189 (aspartic acid) and / or position 1205 (tryptophan). Through cryo-electron microscopy structural analysis and in vitro mismatch experiments, this invention has confirmed that both identified key amino acid sites are involved in regulating the synthetic fidelity of viral polymerase: mutation at N1189 decreases the synthetic fidelity of the polymerase, while mutation at W1205 increases it. This invention not only provides a new target for the development of attenuated vaccines but also provides crucial evidence for elucidating the molecular regulatory mechanisms of RNA virus fidelity.

The invention relates to a Pseudomonas plecoglossicida pldB gene deletion mutant strain and a preparation method and application thereof, and belongs to the technical field of microorganisms and the field of algae preservation, the pldB gene of the mutant strain is deleted or inactivated, the nucleotide sequence of the pldB gene is shown as SEQ ID NO: 1, and the GenBank accession number of the Pseudomonas plecoglossicida is CP031146.1. The virulence of the mutant strain is obviously reduced compared with that of a wild strain of pseudomonas plecoglossicida; the strain can induce appropriate immune response of a host and up-regulate expression of anti-inflammatory factors, is beneficial to relieving immune pathological injury, has good attenuated live vaccine potential, and provides a brand new vaccine candidate strain for prevention and control of the visceral white-spot disease of the large yellow croaker.

The invention discloses a riemerella anatipestifer double-gene deletion attenuated vaccine candidate strain, a construction method and application, the riemerella anatipestifer double-gene deletion attenuated vaccine candidate strain is a riemerella anatipestifer CH-1 strain B739RS01935-B739RS07625 double-gene deletion attenuated vaccine candidate strain, the preservation number is CCTCC NO: M20251080, the preservation date is May 22, 2025, and the preservation number is CCTCC NO: M20251080. The strain is preserved in China Center for Type Culture Collection, and the address of the preservation unit is Wuhan University, Wuhan, China. After ducklings are immunized by the low virulent strain, the low virulent strain has no obvious influence on weight proliferation of the ducklings and has good safety. And after the ducklings are immunized, the challenge protection rate on RACH-1 wild virulent strains reaches 83.3%, and the immune protection effect is good.

The present application relates to a kind of carp herpesvirus II type ORF150 gene deletion strain and its preparation method and application, belong to aquatic animal disease prevention and control technical field.The present application carp herpesvirus II type ORF150 gene deletion strain preservation number is CCTCC NO:V202603, is preserved in China typical culture preservation center, and is named carp herpesvirus 2 type CyHV-2-SS24-Δ150-GFP Cyvirus cyprinidallo2 The virulence of the present application carp herpesvirus II type ORF150 gene deletion strain is significantly weakened, but still retains good immunogenicity, can induce the immune fish body to produce immune protection to carp herpesvirus II type.ORF Therefore, the present application carp herpesvirus II type ORF150 gene deletion strain can be used as live attenuated vaccine to carp herpesvirus II type, prevent koi and its variety in aquaculture from being infected by carp herpesvirus II type and lead to hematopoietic organ necrosis disease.

The present disclosure relates to a viral vector having an exogenous RNA segment having a hairpin-like structure, for example, having two or more base pairing regions separated by one or more non-base pairing regions. The exogenous RNA segment may have a secondary structure, minimum free energy, average position entropy, or other properties within a specified range, or have a value similar to one or more hairpin-like structures of a reference wild-type virus. In some examples, the viral vector is a live attenuated vaccine. In some examples, the viral vectors down-regulate a susceptibility gene in a host plant.

This application relates to a neutralizing monoclonal antibody, hybridoma cell, and application thereof against pseudorabies virus gD protein. This application constructs a PRV gD eukaryotic expression vector, transduces it into CHO cells for expression, and then immunizes animals with PRV gD recombinant protein and a live attenuated vaccine as immunogens to produce a neutralizing monoclonal antibody against PRV gD. The neutralizing monoclonal antibody or hybridoma cell provided herein lays the foundation for the development of rapid detection technologies for pseudorabies virus and its gD protein. These antibodies have broad research and application value and commercial utility in pseudorabies virus-related immunoassays, and provide important guidance for the development of pseudorabies virus-based vaccines.

A natural attenuated strain of infectious laryngotracheitis virus with good safety and good immunogenicity. The natural attenuated strain is named infectious laryngotracheitis virus ILTV FJ19, and has been deposited in the China Center for Type Culture Collection on November 29, 2023, with the deposit number of CCTCC NO: V2023109, and the deposit address of No. 299, Bayi Road, Wuchang District, Wuhan City, Hubei Province. Experiments show that the avian infectious laryngotracheitis virus ILTV FJ19 strain has stable passage ability, can adapt to inoculation via the allantoic cavity route, has very good safety and immunogenicity when inoculated in 14-day-old SPF chickens, can be used for eye-drop inoculation or oral inoculation, and can be used as a candidate strain of a live attenuated vaccine against ILTV.

A system for the rapid development of vaccines or anti-bacterial drugs is required when working with pandemics. The easiest way to formulate these new vaccines is through computational reduction of existing organisms via statistical models. Once vaccine candidates are arrived at through this method, “Super Organisms” containing all of the computationally reducible fragments can then be taken through a Crispr reduction process wherein those computationally reducible fragments are removed. The result is a vaccine candidate which has possible problematic function partially or fully removed. The “neutered” version of the virus, as well as the DNA fragments and their mRNA transcriptions, can then be tested in a lab and in clinical trials for efficacy. This patent covers a vaccine candidate production methodology using computationally reducible fragments removed from Super Organisms either collectively or individually; as well as the DNA fragments themselves and the mRNA transcripts of those fragments.

A lyophilized stabilized formulation containing a live attenuated vaccine strain against tularemia. The method includes supplying the immunogenic agent comprising Fn-igIDOAgFTT and subjecting the immunogenic agent to lyophilization and recovering a lyophilized and stabilized form of such immunogenic agent.

The present disclosure relates to a viral vector having an exogenous RNA segment with a hairpin-like structure, for example having two or more base-paired regions separated by one or more non-base-paired regions. The exogenous RNA segment may have a secondary structure, minimum free energy, average positional entropy or other attributes within specified ranges, or with values similar to one or more hairpin-like structures of a reference wild type virus. In some examples, the viral vector is a live attenuated vaccine. In some examples, the viral vectors downregulates a susceptibility gene in a host plant.

The present invention discloses a monoclonal antibody 2D1B1 against canine distemper virus H protein and its application, belonging to the technical field of monoclonal antibodies. The present invention screened out 9 monoclonal antibodies by indirect ELISA and indirect immunofluorescence identification. After indirect immunofluorescence identification, the 9 monoclonal antibodies obtained were all able to react with the vaccine strain (CDV-Onderstepoort). The results of Western Blot tests showed that the 9 monoclonal antibodies screened out were all able to react specifically with the eukaryotic expressed CDV H protein, among which 2D1B1 was also able to react specifically with the prokaryotic expressed CDV H protein, that is, 2D1B1 was not only able to react with the attenuated vaccine strain and the virulent isolated strain, but also with both eukaryotic and prokaryotic expressed CDV H proteins, and at the same time had a high neutralizing potency (2 6 ), which can be used to prepare broad-spectrum detection reagents and therapeutic preparations for identifying canine distemper virus H protein.

The invention discloses a coronavirus attenuated strain, a vaccine as well as a preparation method and application of the coronavirus attenuated strain. Compared with a natural strain, the coronavirus attenuated strain disclosed by the invention at least comprises deletion of a No.5 stem loop (Stem-loop 5, SL5) from the 131 site to the 350 site of a 5 '-non-coding region (5' UTR) or mutation of any nucleotide maintaining a stem loop structure in a second stem loop from the 175 site to the 299 site of the SL5; compared with a natural strain, the virulence of the SL5-deleted mutant virus strain is obviously reduced; the SL5-deficient mutant virus strain has better genetic stability, and the carried virus genome has no risk of being integrated into the host cell genome. Therefore, the coronavirus attenuated strain disclosed by the invention can be used as an attenuated live vaccine for preventing coronavirus infection, and has a good application prospect.

The invention relates to the technical field of gene engineering, and particularly discloses a serum type 5 haemophilus parasuis attenuated vaccine strain without antibody polygene deletion as well as a construction method and application of the serum type 5 haemophilus parasuis attenuated vaccine strain. According to the invention, crp, cpxAR and OmpP2 genes related to toxicity are deleted from a clinical isolated strain of a haemophilus parasuis serum type 5 virulent strain HN1570 by means of molecular biology to obtain a non-resistant polygene deleted strain HPS5 [delta] OmpP2 [delta] crp [delta] cpxAR, and the deleted strain is preserved; tests find that the attenuated live vaccine prepared by using the HPS5deltaOmpP2 deltacrp deltacpxAR strain haemophilus parasuis as a strain antigen not only has 100% protection rate on infection of type 5, but also has better cross protection force on infection of other serotype haemophilus parasuis and haemophilus parasuis incapable of being classified, and a good immune protection effect can be achieved by using a small immunization amount; the result shows that the haemophilus parasuis HPS5 [delta] OmpP2 [delta] crp [delta] cpxAR strain has good immunogenicity; the vaccine is simple in preparation process, free of resistance genes, free of toxic and side effects, good in safety, long in immune period and good in immune effect, and can be used for industrial production.

This invention discloses a live attenuated vaccine for the prevention of Toxoplasma gondii infection, the active ingredient of which is the tachyzoite of the Toxoplasma gondii RHΔpCaBp1 gene knockout strain. This invention prepares a live attenuated RHΔpCaBp1 vaccine that can be used to prevent Toxoplasma gondii infection in intermediate hosts. Immunization with this live attenuated vaccine, containing 100 Toxoplasma gondii RHΔpCaBp1 tachyzoites, via intraperitoneal injection, showed safety in mice after three immunizations, and demonstrated 100% protection against low-dose virulent strains (intraperitoneal injection of 100 and 500 RH tachyzoites) in the model intermediate host.

The invention discloses an IBDV (Infectious Bursal Disease Virus) mutant based on VP1 protein T425 and R426 synergistic modification and application of the IBDV mutant. The invention identifies that threonine at the 425th site on the VP1 protein is a new phosphorylation site for the first time, and reveals that threonine at the 425th site and adjacent arginine methylation modification at the 426th site have a synergistic positive feedback regulation relationship. Based on the mechanism, a T425 and R426 double-site modification deleted virus mutant is successfully constructed, and the mutant shows a phenotype with severely weakened replication ability. In addition, the invention also provides an antibody capable of specifically recognizing pT425, an application of a GSK-3 kinase inhibitor in inhibition of virus replication, and a related screening and detection method. The invention provides a new target and strategy for developing novel IBDV attenuated vaccines, antiviral drugs and diagnostic reagents.

The present invention relates to a novel recombinant antigen protein for Japanese encephalitis and, more specifically, to a recombinant antigen protein for Japanese encephalitis, designed through protein structural stability analysis and introduction of point mutations. It has been identified that a composition comprising the recombinant antigen protein for Japanese encephalitis, according to the present invention, exhibits immunogenicity and protective efficacy against challenge inoculation that are superior to those of an approved live-attenuated vaccine. In particular, it has been experimentally identified that the recombinant antigen protein for Japanese encephalitis, of the present invention, exhibits excellent protective efficacy against Japanese encephalitis virus G5 and other genotypes. Therefore, the recombinant antigen protein for Japanese encephalitis, of the present invention, can be variously used in the field of preventing infection by Japanese encephalitis virus G1 to G5.